文献速递主动脉疾病

感染性自体腹主动脉瘤腔内治疗的中期结局

Mid-term Outcomes of Endovascular Management of Infective Native Abdominal Aortic Aneurysms.
PubMed 文献 · J Endovasc Ther · 2026-08-27

本研究回顾性分析2020–2025年单中心494例腹主动脉瘤患者中12例(2.4%)感染性自体腹主动脉瘤接受EVAR的中期结局。技术成功率100%,中位随访23.8个月,9/11例(81.8%)囊腔完全回缩,无再干预,3例死亡均非主动脉相关。CRP显著下降、PET-CT转阴和囊腔回缩支持感染控制,延长但有限疗程抗生素在密切监测下可能足够。

要点

  • EVAR治疗感染性自体腹主动脉瘤技术成功率高,中期感染控制持久。
  • CRP正常化、PET-CT转阴和囊腔回缩支持细菌根除。
  • 密切监测下延长但有限疗程抗生素可能适用于部分患者。

核心结论

  • EVAR治疗感染性自体腹主动脉瘤获得高技术成功率和持久的中期感染控制。
  • CRP正常化、PET-CT转阴和囊腔回缩支持细菌根除。
  • 在精选且密切监测的患者中,延长但有限疗程的抗生素治疗可能足够。

研究设计与样本

  • 回顾性单中心研究,纳入2020至2025年在该机构诊断为感染性自体腹主动脉瘤并接受EVAR的所有患者。
  • 共494例腹主动脉瘤患者中12例(2.4%)为感染性自体腹主动脉瘤,中位年龄75岁(IQR 69–77),83%为男性。
  • 分析人口学、微生物学、炎症标志物、影像学特征、技术结局和随访数据,配对连续变量采用Wilcoxon符号秩检验。

主要发现

  • 50%病例鉴定出沙门氏菌属。
  • 所有动脉瘤均为肾下型,中位直径48 mm(IQR 37–51);所有患者存在主动脉周围软组织肿块,6例呈囊状形态,4例快速扩张。
  • 技术成功率100%;1例发生急性肾损伤,1例死于肠系膜缺血(8.3%)。

临床怎么用

  • EVAR可作为精选感染性自体腹主动脉瘤患者的有效且微创的治疗选择。
  • 需识别潜在感染灶,并保持血管外科与感染科团队的密切协作以优化结局。
  • 延长但有限疗程的抗生素治疗需配合密切监测,CRP、PET-CT和囊腔回缩可用于指导感染控制评估。

局限性

  • 回顾性单中心设计,样本量小(12例),结果需谨慎外推。
  • 部分患者随访时间有限,抗生素疗程和停药策略未标准化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: To evaluate outcomes of endovascular aneurysm repair (EVAR) for infective native abdominal aortic aneurysms (INAAA) and to describe microbiological, imaging, and inflammatory findings, as well as the role of prolonged antibiotic therapy and fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET-CT) in follow-up. METHODS: This retrospective single-center experience included all patients diagnosed with INAAA and treated with EVAR at our institution between 2020 and 2025. Demographics, microbiology, inflammatory markers, imaging characteristics, technical outcomes, and follow-up data were analyzed. Descriptive statistics were used, and paired continuous variables were compared using the Wilcoxon signed-rank test. RESULTS: Among 494 patients treated for abdominal aortic aneurysm, 12 (2.4%) presented with INAAA. Median age was 75 years (interquartile range [IQR], 69-77), and 83% were male. Salmonella species were identified in 50% of cases. Median white blood cells count at admission was 12.5 × 109/L (IQR, 8.5-14.3), decreasing to 8.8 × 109/L at discharge (P = .26). C-reactive protein decreased significantly from 141.7 mg/L (IQR, 116.6-263.9) to 24.8 mg/L (IQR, 16.1-92.3; P = .002). All aneurysms were infrarenal, with a median diameter of 48 mm (IQR, 37-51); imaging features included periaortic soft-tissue mass in all patients, saccular morphology in 6 patients, and rapid aneurysm expansion in 4 patients. Technical success was 100%. One patient developed acute kidney injury, and another died from mesenteric ischemia (8.3%). Median follow-up (FU) was 23.8 months (IQR, 5.9-52.8). Complete sac regression occurred in 9 of 11 (81.8%) cases, and the median time to visual PET-CT assessment demonstrating resolution of abnormal FDG uptake was 6.3 months (IQR, 3.9-15.5). Median time of antibiotic treatment was 14.6 months (IQR, 5.4-30.1). Five patients remained on antibiotic therapy, while 3 had it safely discontinued after more than 1 year. During FU, no reinterventions were recorded, and 3 deaths were observed, all non-aortic related. CONCLUSION: Endovascular aneurysm repair for INAAA achieved high technical success and durable mid-term infection control. C-reactive protein normalization, PET-CT negativity, and sac regression supported bacterial eradication. Extended but finite antibiotic therapy may be adequate in selected, well-monitored patients.Clinical ImpactEndovascular aneurysm repair (EVAR) offers an effective and less invasive treatment option for infective native abdominal aortic aneurysms (INAAA), traditionally associated with high morbidity and mortality after open repair. In this series, EVAR achieved complete technical success and durable infection control, supported by rapid CRP decline, sac regression, and PET-CT normalization. Identifying a potential infection focus and maintaining close collaboration between vascular and infectious disease teams were essential to favorable outcomes. These results reinforce EVAR as a safe, durable, and clinically meaningful strategy for selected patients with INAAA when coupled with prolonged, carefully monitored antibiotic therapy.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Bilman V, Rottenberg A, Davidov I, et al. Mid-term Outcomes of Endovascular Management of Infective Native Abdominal Aortic Aneurysms. J Endovasc Ther. 2026. PMID: 42661153. doi:10.1177/15266028261479311

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。